Skip to main content
Erschienen in: Digestive Diseases and Sciences 1/2018

13.11.2017 | Original Article

Fecal Transplantation for Treatment of Clostridium Difficile Infection in Elderly and Debilitated Patients

verfasst von: Tali Friedman-Korn, Dan Meir Livovsky, Nitsan Maharshak, Nathaniel Aviv Cohen, Kalman Paz, Ariella Bar-Gil Shitrit, Eran Goldin, Benjamin Koslowsky

Erschienen in: Digestive Diseases and Sciences | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Fecal microbiota transplantation (FMT) is a new technique recently introduced to treat recurrent Clostridium difficile infection (CDI). Little is known about the efficacy and risks of FMT in elderly and ill patients.

Aim

To investigate FMT efficacy in ill and elderly patients compared to conventional treatment.

Methods

The study comprised two groups of patients between 2012 and 2016 with recurrent CDI at two medical centers in Israel. The study group received FMT and the controls conventional therapy. The primary end points were CDI recurrence, length of hospitalization, and short-term survival.

Results

Thirty-four patients altogether, (21 females, mean age 82 years) participated, 11 received FMT and 23 controls. Demographics and clinical characteristics were similar between the two groups. Comorbidity indexes, i.e., Charlson index was high in both groups. In the FMT group, 10/11 (90%) patients showed clinical improvement 3 days after initiating treatment compared to 9/23 (39%) in the control group, p = 0.02. Survival at 2 months did not differ between the groups (FMT 54%, Control 50%, p = 0.816), but mean survival in the FMT group was higher than in the control (12 vs. 4 months, respectively, p = 0.015). Two significant adverse events from the FMT group included suspected aspirations, both occurring during gastroscopy route of administration.

Conclusions

FMT is effective for elderly and very ill patients. Safety is a concern, but is rare even in patients with much comorbidity. Colonoscopy may be the preferred route of FMT infusion.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat. Rev. Microbiol. 2009;7:526–536.CrossRefPubMed Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat. Rev. Microbiol. 2009;7:526–536.CrossRefPubMed
3.
Zurück zum Zitat Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N. Engl. J. Med. 2015;372:825–834.CrossRefPubMed Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N. Engl. J. Med. 2015;372:825–834.CrossRefPubMed
5.
Zurück zum Zitat Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am. J. Gastroenterol. 2013;108:478–498. (quiz 499).CrossRefPubMed Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am. J. Gastroenterol. 2013;108:478–498. (quiz 499).CrossRefPubMed
6.
Zurück zum Zitat Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin. Infect. Dis: Off. Publ. Infect. Dis. Soc. Am. 2011;53:994–1002.CrossRef Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin. Infect. Dis: Off. Publ. Infect. Dis. Soc. Am. 2011;53:994–1002.CrossRef
7.
Zurück zum Zitat Kelly CP, LaMont JT. Clostridium difficile–more difficult than ever. N. Engl. J. Med. 2008;359:1932–1940.CrossRefPubMed Kelly CP, LaMont JT. Clostridium difficile–more difficult than ever. N. Engl. J. Med. 2008;359:1932–1940.CrossRefPubMed
8.
Zurück zum Zitat Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet. 2001;357:189–193.CrossRefPubMed Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet. 2001;357:189–193.CrossRefPubMed
9.
Zurück zum Zitat Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. J. Infect. Dis. 2008;197:435–438.CrossRefPubMed Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. J. Infect. Dis. 2008;197:435–438.CrossRefPubMed
10.
Zurück zum Zitat Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery. 1958;44:854–859.PubMed Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery. 1958;44:854–859.PubMed
11.
Zurück zum Zitat Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2003;36:580–585.CrossRef Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2003;36:580–585.CrossRef
12.
Zurück zum Zitat Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc. 2011;9:1044–1049. Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc. 2011;9:1044–1049.
13.
Zurück zum Zitat Rohlke F, Stollman N. Fecal microbiota transplantation in relapsing Clostridium difficile infection. Ther. Adv. Gastroenterol. 2012;5:403–420.CrossRef Rohlke F, Stollman N. Fecal microbiota transplantation in relapsing Clostridium difficile infection. Ther. Adv. Gastroenterol. 2012;5:403–420.CrossRef
14.
Zurück zum Zitat Choi HH, Cho YS. Fecal microbiota transplantation: current applications, effectiveness, and future perspectives. Clin. Endosc. 2016;49:257–265.CrossRefPubMedPubMedCentral Choi HH, Cho YS. Fecal microbiota transplantation: current applications, effectiveness, and future perspectives. Clin. Endosc. 2016;49:257–265.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Karadsheh Z, Sule S. Fecal transplantation for the treatment of recurrent clostridium difficile infection. North Am. J. Med. Sci. 2013;5:339–343.CrossRef Karadsheh Z, Sule S. Fecal transplantation for the treatment of recurrent clostridium difficile infection. North Am. J. Med. Sci. 2013;5:339–343.CrossRef
16.
Zurück zum Zitat Hirsch BE, Saraiya N, Poeth K, Schwartz RM, Epstein ME, Honig G. Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection. BMC Infect. Dis. 2015;15:191.CrossRefPubMedPubMedCentral Hirsch BE, Saraiya N, Poeth K, Schwartz RM, Epstein ME, Honig G. Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection. BMC Infect. Dis. 2015;15:191.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA. 2014;312:1772–1778.CrossRefPubMed Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA. 2014;312:1772–1778.CrossRefPubMed
18.
Zurück zum Zitat Youngster I, Mahabamunuge J, Systrom HK, et al. Oral, frozen fecal microbiota transplant (FMT) capsules for recurrent Clostridium difficile infection. BMC Med. 2016;14:134.CrossRefPubMedPubMedCentral Youngster I, Mahabamunuge J, Systrom HK, et al. Oral, frozen fecal microbiota transplant (FMT) capsules for recurrent Clostridium difficile infection. BMC Med. 2016;14:134.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 2013;368:407–415.CrossRefPubMed van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 2013;368:407–415.CrossRefPubMed
20.
Zurück zum Zitat Cammarota G, Masucci L, Ianiro G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy versus vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment. Pharmacol. Ther. 2015;41:835–843.CrossRefPubMed Cammarota G, Masucci L, Ianiro G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy versus vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment. Pharmacol. Ther. 2015;41:835–843.CrossRefPubMed
21.
Zurück zum Zitat Marshall LL, Peasah S, Stevens GA. Clostridium difficile Infection in older adults: systematic review of efforts to reduce occurrence and improve outcomes. Consult. Pharm. J. Am. Soc. Consult. Pharm. 2017;32:24–41.CrossRef Marshall LL, Peasah S, Stevens GA. Clostridium difficile Infection in older adults: systematic review of efforts to reduce occurrence and improve outcomes. Consult. Pharm. J. Am. Soc. Consult. Pharm. 2017;32:24–41.CrossRef
22.
Zurück zum Zitat Tauxe WM, Haydek JP, Rebolledo PA, et al. Fecal microbiota transplant for Clostridium difficile infection in older adults. Ther. Adv. Gastroenterol. 2016;9:273–281.CrossRef Tauxe WM, Haydek JP, Rebolledo PA, et al. Fecal microbiota transplant for Clostridium difficile infection in older adults. Ther. Adv. Gastroenterol. 2016;9:273–281.CrossRef
23.
Zurück zum Zitat Frenkel WJ, Jongerius EJ, Mandjes-van Uitert MJ, van Munster BC, de Rooij SE. Validation of the Charlson Comorbidity Index in acutely hospitalized elderly adults: a prospective cohort study. J. Am. Geriatr. Soc. 2014;62:342–346.CrossRefPubMed Frenkel WJ, Jongerius EJ, Mandjes-van Uitert MJ, van Munster BC, de Rooij SE. Validation of the Charlson Comorbidity Index in acutely hospitalized elderly adults: a prospective cohort study. J. Am. Geriatr. Soc. 2014;62:342–346.CrossRefPubMed
24.
Zurück zum Zitat Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur. J. Cancer. 1996;32A:1135–1141.CrossRefPubMed Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur. J. Cancer. 1996;32A:1135–1141.CrossRefPubMed
25.
Zurück zum Zitat Park SH, Lee YS, Kwon YM. Predictive validity of pressure ulcer risk assessment tools for elderly: a meta-analysis. West. J. Nurs. Res. 2016;38:459–483.CrossRefPubMed Park SH, Lee YS, Kwon YM. Predictive validity of pressure ulcer risk assessment tools for elderly: a meta-analysis. West. J. Nurs. Res. 2016;38:459–483.CrossRefPubMed
Metadaten
Titel
Fecal Transplantation for Treatment of Clostridium Difficile Infection in Elderly and Debilitated Patients
verfasst von
Tali Friedman-Korn
Dan Meir Livovsky
Nitsan Maharshak
Nathaniel Aviv Cohen
Kalman Paz
Ariella Bar-Gil Shitrit
Eran Goldin
Benjamin Koslowsky
Publikationsdatum
13.11.2017
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 1/2018
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-017-4833-2

Weitere Artikel der Ausgabe 1/2018

Digestive Diseases and Sciences 1/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.